Actavis Inc (ACT) 285.37 $ACT
Actavis Leads IBD 50 Stocks With Earnings This Week
at Investor's Business Daily - Sat Feb 14, 7:02AM CST
Earnings season is still chugging along past Presidents Day, with several major drugmakers and technology companies yet to disclose eagerly anticipated results. Today's IBD 50 roundup takes a peek at two hot biotechs and one laser-focused tech firm...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), PCYC: 163.28 (+0.23), AKRX: 47.28 (-0.25), JAZZ: 169.69 (+6.89), IPGP: 87.26 (+0.07)
Jim Cramer's Top Stock Picks: ACT PCLN CLX HAIN WWAV NVAX
at The Street - Sat Feb 14, 5:00AM CST
Cramer says buy Priceline after it reports earnings but before the conference call, and Clorox is the winner in the consumer packaged-goods sector.
WWAV: 38.65 (+0.61), HAIN: 59.48 (+0.45), ACT: 285.37 (+3.71), CLX: 109.00 (+0.74), NVAX: 8.80 (+0.40), PCLN: 1,103.37 (+11.42)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Feb 13, 7:03PM CST
Cramer will be doing a lot of listening to what companies have to say about their business.
ACT: 285.37 (+3.71), BDX: 143.71 (+0.72), SE: 36.81 (+0.61), RRGB: 77.77 (-0.20), CLX: 109.00 (+0.74), WMT: 85.81 (-0.08), STZ: 113.03 (-0.48), SAM: 303.26 (-0.97), PLKI: 61.07 (+0.44), WM: 51.29 (-1.41), PCLN: 1,103.37 (+11.42), FOSL: 98.44 (-0.30), GT: 25.91 (-0.30), COG: 28.10 (+0.18), NVAX: 8.80 (+0.40), DE: 90.04 (+0.67), EOG: 96.92 (+2.12), JWN: 79.41 (+0.04), PG: 85.90 (-0.13), CL: 70.08 (+0.23)
Actavis Launches Generic Pulmicort RESPULES®
PR Newswire - Fri Feb 13, 3:28PM CST
Actavis plc (NYSE: ACT) today announced that it has launched its generic version of AstraZeneca's Pulmicort RESPULES® (budesonide inhalation suspension) 0.25 and 0.5 mg vials following a ruling from the United States District Court for the District of New Jersey that (i) United States Patent No. 7,524,834 is invalid, and (ii) AstraZeneca's request for a permanent injunction is denied.
ACT: 285.37 (+3.71)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
FDA accepts Pfizer's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:22AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
Ackman vs. Icahn: How Two Billionaires, Former Adversaries, Stack Up
at The Street - Fri Feb 13, 10:14AM CST
More than two years have passed since Icahn and Ackman's epic CNBC blowout. Though they've since called a truce, it's worth looking at how these two billionaires stack up today.
AGN: 229.49 (+1.87), HLF: 32.78 (-0.84), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), EBAY: 56.47 (+1.73), GCI: 34.77 (-0.07), IEP: 100.21 (+0.28), MTW: 21.86 (+0.34), AAPL: 127.08 (+0.62)
Will Masimo Corp (MASI) Disappoint Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 9:30AM CST
Our proven model does not conclusively show that Masimo Corp (MASI) is likely to beat earnings this quarter.
BLUE: 90.70 (+0.93), ACT: 285.37 (+3.71), MASI: 27.38 (-0.21), HLS: 45.01 (+0.30)
Can Radius Health (RDUS) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 9:06AM CST
Radius Health, Inc. (RDUS) is expected to report its fourth-quarter and full-year 2014 results on Feb 16 and carries an Earnings ESP of +5.00%.
RDUS: 50.37 (+0.63), IPXL: 39.51 (+0.69), ACT: 285.37 (+3.71), ARIA: 7.35 (+0.45)
Actavis divests pharma outsourcing business to private equity firm
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 8:45AM CST
ACT: 285.37 (+3.71)
Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:22AM CST
Ironwood Pharmaceuticals (IRWD) reported a loss of 27 cents per share in the fourth quarter of 2014, wider than the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), IRWD: 15.15 (-0.85), ACHN: 10.89 (-0.20)
Actavis to Divest Pharmatech to TPG
PR Newswire - Fri Feb 13, 7:30AM CST
Actavis plc (NYSE: ACT) and TPG, the global private investment firm, today announced that they have entered into definitive agreements, under which Actavis will divest to TPG the business currently known as Aptalis Pharmaceutical Technologies (Pharmatech) -- a pharmaceutical outsourcing and R&D business within Actavis' subsidiary Aptalis operating in the United States, Canada and Europe (where the transaction is, in certain jurisdictions, still subject to local regulations, discussions and clearances). No other Aptalis businesses or products are included in the transaction. No financial terms were disclosed.
ACT: 285.37 (+3.71)
Don't Discount Bill Ackman
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 11:13AM CST
Originally Published on January 28, 2015 Bill Ackman wears an almost punchably smug expression. He looks as if he thinks that he is the smartest guy in any room. All the more grating is the fact that, in most rooms, he is right. He has reasons to...
ZTS: 45.46 (-0.33), AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), HHC: 144.41 (+6.41), TPRE: 13.91 (+0.03), PAH: 22.68 (+0.14), CP: 186.30 (-0.54), APD: 152.81 (+0.59), GLRE: 31.99 (+0.01)
Will Kite Pharma (KITE) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:40AM CST
Kite Pharma, Inc. (KITE) is expected to report fourth-quarter 2014 results on Feb 13.
ACT: 285.37 (+3.71), KITE: 62.59 (+0.82), AMGN: 153.48 (+0.30), ACOR: 36.14 (-0.51)
CVRs - The Good, The Bad And The Ugly
Chris DeMuth Jr. - at Seeking Alpha - Wed Feb 11, 12:40AM CST
AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), KR: 72.86 (+0.41), SWY: 35.10 (-0.04), GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Actavis to Divest U.S. Rights of Doryx to Mayne Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:41PM CST
Actavis (ACT) to divest U.S. rights of Doryx brand to Mayne Pharma, to boost focus on core areas.
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), AZN: 69.96 (+0.20)
DaVita Healthcare (DVA): What's in Store for Q4 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:30PM CST
DaVita Healthcare Partners Inc. (DVA) is set to report fourth-quarter and full-year 2014 earnings results on Feb 12, 2015.
ACT: 285.37 (+3.71), LPNT: 69.04 (-0.06), DVA: 73.10 (-3.29), ACOR: 36.14 (-0.51)
Will Immune Design (IMDZ) Miss on Earnings This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 1:40PM CST
Immune Design (IMDZ) is expected to report fourth-quarter 2014 results on Feb 11, 2015 and holds a Zacks Rank #4 (Sell) with an Earnings ESP of 0.00%.
IMDZ: 25.34 (+1.20), ACT: 285.37 (+3.71), ARIA: 7.35 (+0.45), SNY: 49.42 (+0.82)
Will Pfizer Inc. Break Up in 2015?
George Budwell, The Motley Fool - Motley Fool - Tue Feb 10, 11:59AM CST
Source: Flickr via user William Murphy. Pfizer is the world's largest drugmaker, reporting nearly $50 billion in sales last year. Even so, its stock has drastically underperformed the broader market over the past decade: The pharma...
ZTS: 45.46 (-0.33), ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56)
World Intravenous (IV) Iron Drugs Industry
PR Newswire - Tue Feb 10, 11:39AM CST
This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 17 companies including many key and niche players such as -
ACT: 285.37 (+3.71), AMAG: 41.49 (+0.23)
Actavis Leads IBD 50 Stocks With Earnings This Week
at Investor's Business Daily - Sat Feb 14, 7:02AM CST
Earnings season is still chugging along past Presidents Day, with several major drugmakers and technology companies yet to disclose eagerly anticipated results. Today's IBD 50 roundup takes a peek at two hot biotechs and one laser-focused tech firm...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), PCYC: 163.28 (+0.23), AKRX: 47.28 (-0.25), JAZZ: 169.69 (+6.89), IPGP: 87.26 (+0.07)
Jim Cramer's Top Stock Picks: ACT PCLN CLX HAIN WWAV NVAX
at The Street - Sat Feb 14, 5:00AM CST
Cramer says buy Priceline after it reports earnings but before the conference call, and Clorox is the winner in the consumer packaged-goods sector.
WWAV: 38.65 (+0.61), HAIN: 59.48 (+0.45), ACT: 285.37 (+3.71), CLX: 109.00 (+0.74), NVAX: 8.80 (+0.40), PCLN: 1,103.37 (+11.42)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Feb 13, 7:03PM CST
Cramer will be doing a lot of listening to what companies have to say about their business.
ACT: 285.37 (+3.71), BDX: 143.71 (+0.72), SE: 36.81 (+0.61), RRGB: 77.77 (-0.20), CLX: 109.00 (+0.74), WMT: 85.81 (-0.08), STZ: 113.03 (-0.48), SAM: 303.26 (-0.97), PLKI: 61.07 (+0.44), WM: 51.29 (-1.41), PCLN: 1,103.37 (+11.42), FOSL: 98.44 (-0.30), GT: 25.91 (-0.30), COG: 28.10 (+0.18), NVAX: 8.80 (+0.40), DE: 90.04 (+0.67), EOG: 96.92 (+2.12), JWN: 79.41 (+0.04), PG: 85.90 (-0.13), CL: 70.08 (+0.23)
Actavis Launches Generic Pulmicort RESPULES®
PR Newswire - Fri Feb 13, 3:28PM CST
Actavis plc (NYSE: ACT) today announced that it has launched its generic version of AstraZeneca's Pulmicort RESPULES® (budesonide inhalation suspension) 0.25 and 0.5 mg vials following a ruling from the United States District Court for the District of New Jersey that (i) United States Patent No. 7,524,834 is invalid, and (ii) AstraZeneca's request for a permanent injunction is denied.
ACT: 285.37 (+3.71)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
FDA accepts Pfizer's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:22AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
Ackman vs. Icahn: How Two Billionaires, Former Adversaries, Stack Up
at The Street - Fri Feb 13, 10:14AM CST
More than two years have passed since Icahn and Ackman's epic CNBC blowout. Though they've since called a truce, it's worth looking at how these two billionaires stack up today.
AGN: 229.49 (+1.87), HLF: 32.78 (-0.84), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), EBAY: 56.47 (+1.73), GCI: 34.77 (-0.07), IEP: 100.21 (+0.28), MTW: 21.86 (+0.34), AAPL: 127.08 (+0.62)
Will Masimo Corp (MASI) Disappoint Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 9:30AM CST
Our proven model does not conclusively show that Masimo Corp (MASI) is likely to beat earnings this quarter.
BLUE: 90.70 (+0.93), ACT: 285.37 (+3.71), MASI: 27.38 (-0.21), HLS: 45.01 (+0.30)
Can Radius Health (RDUS) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 9:06AM CST
Radius Health, Inc. (RDUS) is expected to report its fourth-quarter and full-year 2014 results on Feb 16 and carries an Earnings ESP of +5.00%.
RDUS: 50.37 (+0.63), IPXL: 39.51 (+0.69), ACT: 285.37 (+3.71), ARIA: 7.35 (+0.45)
Actavis divests pharma outsourcing business to private equity firm
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 8:45AM CST
ACT: 285.37 (+3.71)
Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:22AM CST
Ironwood Pharmaceuticals (IRWD) reported a loss of 27 cents per share in the fourth quarter of 2014, wider than the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), IRWD: 15.15 (-0.85), ACHN: 10.89 (-0.20)
Actavis to Divest Pharmatech to TPG
PR Newswire - Fri Feb 13, 7:30AM CST
Actavis plc (NYSE: ACT) and TPG, the global private investment firm, today announced that they have entered into definitive agreements, under which Actavis will divest to TPG the business currently known as Aptalis Pharmaceutical Technologies (Pharmatech) -- a pharmaceutical outsourcing and R&D business within Actavis' subsidiary Aptalis operating in the United States, Canada and Europe (where the transaction is, in certain jurisdictions, still subject to local regulations, discussions and clearances). No other Aptalis businesses or products are included in the transaction. No financial terms were disclosed.
ACT: 285.37 (+3.71)
Don't Discount Bill Ackman
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 11:13AM CST
Originally Published on January 28, 2015 Bill Ackman wears an almost punchably smug expression. He looks as if he thinks that he is the smartest guy in any room. All the more grating is the fact that, in most rooms, he is right. He has reasons to...
ZTS: 45.46 (-0.33), AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), HHC: 144.41 (+6.41), TPRE: 13.91 (+0.03), PAH: 22.68 (+0.14), CP: 186.30 (-0.54), APD: 152.81 (+0.59), GLRE: 31.99 (+0.01)
Will Kite Pharma (KITE) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:40AM CST
Kite Pharma, Inc. (KITE) is expected to report fourth-quarter 2014 results on Feb 13.
ACT: 285.37 (+3.71), KITE: 62.59 (+0.82), AMGN: 153.48 (+0.30), ACOR: 36.14 (-0.51)
CVRs - The Good, The Bad And The Ugly
Chris DeMuth Jr. - at Seeking Alpha - Wed Feb 11, 12:40AM CST
AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), KR: 72.86 (+0.41), SWY: 35.10 (-0.04), GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Actavis to Divest U.S. Rights of Doryx to Mayne Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:41PM CST
Actavis (ACT) to divest U.S. rights of Doryx brand to Mayne Pharma, to boost focus on core areas.
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), AZN: 69.96 (+0.20)
DaVita Healthcare (DVA): What's in Store for Q4 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:30PM CST
DaVita Healthcare Partners Inc. (DVA) is set to report fourth-quarter and full-year 2014 earnings results on Feb 12, 2015.
ACT: 285.37 (+3.71), LPNT: 69.04 (-0.06), DVA: 73.10 (-3.29), ACOR: 36.14 (-0.51)
Will Immune Design (IMDZ) Miss on Earnings This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 1:40PM CST
Immune Design (IMDZ) is expected to report fourth-quarter 2014 results on Feb 11, 2015 and holds a Zacks Rank #4 (Sell) with an Earnings ESP of 0.00%.
IMDZ: 25.34 (+1.20), ACT: 285.37 (+3.71), ARIA: 7.35 (+0.45), SNY: 49.42 (+0.82)
Will Pfizer Inc. Break Up in 2015?
George Budwell, The Motley Fool - Motley Fool - Tue Feb 10, 11:59AM CST
Source: Flickr via user William Murphy. Pfizer is the world's largest drugmaker, reporting nearly $50 billion in sales last year. Even so, its stock has drastically underperformed the broader market over the past decade: The pharma...
ZTS: 45.46 (-0.33), ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56)
World Intravenous (IV) Iron Drugs Industry
PR Newswire - Tue Feb 10, 11:39AM CST
This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 17 companies including many key and niche players such as -
ACT: 285.37 (+3.71), AMAG: 41.49 (+0.23)
